by Estrogen blockers, also known as anti-estrogens, are a class of drugs that inhibit the effects of estrogen in the body. They help reduce the risk of breast cancer recurrence and bone loss in postmenopausal women. Estrogen blockers prevent estrogen from attaching to estrogen receptors in breast tissue and bone. Commonly prescribed estrogen blockers include tamoxifen, toremifene, and aromatase inhibitors such as anastrozole, letrozole, and exemestane.
The global Estrogen Blockers market is estimated to be valued at US$ 15.02 Billion in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the estrogen blockers market is the increasing demand for aromatase inhibitors. Aromatase inhibitors are a newer class of anti-estrogens that are increasingly favored over tamoxifen as they are associated with fewer side effects. Aromatase inhibitors work by blocking the aromatase enzyme responsible for synthesizing estrogens in peripheral tissues like fat. This effectively lowers estrogen levels in postmenopausal women to reduce the risk of breast cancer recurrence. Due to their favorable safety profile, use of aromatase inhibitors such as anastrozole and letrozole is increasing among postmenopausal breast cancer patients worldwide. This rising preference for aromatase inhibitors over tamoxifen is expected to drive the growth of the estrogen blockers market during the forecast period.
Porter’s Analysis
Threat of new entrants: Low threat as this market requires significant investment in R&D, clinical trials, distribution network and brand reputation.
Bargaining power of buyers: Moderate bargaining power due to presence of many established players offering substitutable products. Price sensitivity is medium.
Bargaining power of suppliers: Low bargaining power due to presence of many suppliers and raw material producers. Suppliers do not have significant influence over pricing.
Threat of new substitutes: Moderate threat as other therapeutics are available for hormone dependent cancer treatments. However, estrogen blockers have strong brand image and clinical efficacy.
Competitive rivalry: High rivalry due to presence of many global and local players like Pfizer, AstraZeneca, etc. competing on basis of pricing, innovation, and brand image.
Key Takeaways
The Global Estrogen Blockers Market Size is expected to witness high growth. The global Estrogen Blockers market is estimated to be valued at US$ 15.02 Billion in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis:
North America dominates the market due to increasing breast cancer incidence. Asia Pacific is expected to grow at fastest pace owing to rising healthcare spending and growing medical tourism.
Key players:
Key players operating in the Estrogen Blockers market are Pfizer, AstraZeneca, Sanofi, Teva Pharmaceutical, AbbVie, Fresenius Kabi, Bayer, Actavis. Pfizer leads with its best-selling drug tamoxifen. AstraZeneca’s Arimidex is also a top-selling product.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
